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Abstract 
Purpose: To assess hospital pharmacists’ knowledge of, attitude to, and experience with 
pharmacovigilance and adverse drug reactions (ADRs) in Al Madinah Al Munawarah region, Saudi 
Arabia. 
Methods: A cross-sectional study was conducted from April – June 2015 among hospital pharmacists 
using a self-administered questionnaire. All pharmacists working in government hospitals and primary 
care centers in Al Madinah Al Munawarah region were targeted to participate in the study. A total of 130 
pharmacists were included in the study. Data analysis was conducted using the Statistical Package for 
Social Sciences, version 20. 
Results: The response rate to the survey was 79 % out of 103 pharmacists. In terms of knowledge 
about pharmacovigilance, only 56 (54.4 %) correctly identified WHO definition of ADRs, while 53 (51.5 
%) of the pharmacists correctly defined pharmacovigilance. Regarding pharmacists’ experience with 
ADR reporting, less than half (N = 46, 44.7 %) said they have made a suspected ADR report and 
slightly less than half of the pharmacists (50, 48.5 %) said they are familiar with Saudi Food and Drug 
Authority (SFDA) system of suspected ADR reporting. The majority of the pharmacists (N = 95, 92.2 %) 
believed that patient safety is the most important goal of suspected ADR reporting. The most common 
barrier to ADR reporting was lack of pharmacovigilance training (N = 48, 46.6 %). 
Conclusion: Pharmacists had insufficient knowledge of, but positive attitude toward pharmacovigilance 
and ADR reporting. Lack of pharmacovigilance training has been identified as the major barrier to ADR 
reporting. 
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As defined by the World Health Organization 
(WHO) “Pharmacovigilance is the science and 
activities relating to the detection, assessment, 
understanding and prevention of adverse effects 
or any other drug-related problems” [1].  In Saudi 
Arabia, the Saudi Food and Drug Authority 
(SFDA) is the main authority that is responsible 
for the safety of food and drugs for humans and 
animals [2].  The safety of post-marketed 
medications in Saudi Arabia is monitored by the 
National Pharmacovigilance and Drug Safety 
Center through the Saudi Adverse Event 
Reporting System (SAERS) [3].  Healthcare 
professionals, patients, and drug manufacturers 
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should submit their reports about any suspected 
adverse drug reactions (ADRs) to the SAERS 
using special forms designed by the National 
Pharmacovigilance and Drug Safety Center. 
 
ADRs are the main cause of hospital admissions 
[4-7]. The early detection and assessment of 
ADRs through raising the awareness of 
healthcare professionals about the necessity and 
advantages of reporting to improve patient safety 
are highly encouraged [8]. However, several 
factors have been identified as discouraging 
ADR reporting. A poor understanding and lack of 
knowledge of the ADR reporting process, the 
unavailability of ADR reporting forms, the 
misconception that ADR reporting is the 
responsibility of physicians, and the fear of 
liability have been reported as factors 
discouraging ADR reporting in Saudi Arabia [9-
11]. 
 
A recent qualitative study has identified several 
challenges to pharmacovigilance, such as a lack 
of knowledge of the significance of ADR 
reporting, workloads, and a lack of collaboration 
between regulatory bodies and the hospitals [12]. 
Internationally, other challenges exist, including 
uncertainty about whether the event is drug-
related, the underestimation of ADR seriousness, 
being too busy to report an ADR, and a lack of 
awareness of the process of ADR reporting [13-
18].    
 
To improve ADR reporting, it is essential to 
assess the baseline knowledge, attitudes, and 
practices of hospital pharmacists regarding 
pharmacovigilance. Therefore, this study was 
conducted to evaluate hospital pharmacists’ 
knowledge of, attitudes toward, and experiences 
with ADR reporting and pharmacovigilance, and 
they were asked what factors might be helpful to 




Study design and setting 
 
This was a cross-sectional study conducted from 
April–June 2015 among 103 pharmacists 
working in 11 government hospitals and primary 
care centers in the Al Madinah Al Munawarah 
region, Saudi Arabia. Of these hospitals, nine 
were affiliated to Saudi Ministry of Health, one to 
National Guard and another to Ministry of 
Defense. Seven were primary care centres 
affiliated to Ministry of Health, while three were 
medical centres; of the latter, two were affiliated 
to Ministry of Education and the second to 
Ministry of Interior in Al Madinah Al Munawarah 
region, Saudi Arabia. 
Study tool 
 
The study questionnaire consisted of six 
sections, including demographic information, 
knowledge, experience, attitudes, barriers, and 
factors encouraging ADR reporting. Pharmacists’ 
knowledge about ADRs was assessed by asking 
them to choose the correct definition of an ADR 
according to the WHO, to define 
pharmacovigilance in their own words, and to 
identify the differences between ADRs and 
medication errors. Pharmacists’ experiences with 
ADR reporting were assessed by asking eight 
related questions. Pharmacists’ attitudes toward 
ADR reporting were assessed by asking three 
multiple-choice questions. The questions include 
the most important goals of reporting suspected 
ADRs and motivations to report ADRs. Barriers 
to ADR reporting were assessed by providing a 
list of barriers and by asking pharmacists to 
choose one or more answers. An open-ended 
question was asked of the pharmacists regarding 
the factors encouraging ADR reporting. The 
content validity of the questionnaire was 




All pharmacists working in government hospitals 
and primary care centers in the Al Madinah Al 
Munawarah region were targeted to participate in 
this study. One of the authors visited each 
hospital, explained the aims of the study to the 
pharmacists, and thereafter asked them to 
participate in the study. Those who agreed to 
participate in the study were given a copy of the 
self-administered questionnaire to be completed 
and returned. The participants’ identities were 
not revealed to anybody, nor were their names 
asked to be included in the questionnaire to 
protect the confidentiality of the information. 
Informed consent was obtained from each 
participant. In addition, participants were 
informed that participation in the study is 
voluntary, that the purpose of the study is not to 
evaluate their institution, and that no authority will 




Ethical approval (ref. no. 68 /27-1-1436) was 
obtained from Research and Ethics Committee of 
the General Directorate of Health Affairs, Al 




Descriptive statistics were used to analyze the 
data (frequency and percentages). Statistical 
analysis was performed using Statistical 
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Package for Social Sciences (SPSS) for 




In total, 130 pharmacists working in government 
hospitals and primary care centers in the Al 
Madinah Al Munawarah region were approached 
to participate in the study, and 103 (79 %) 
responded to the survey. The majority of the 
pharmacists were working for Ministry of Health 
(MOH) hospitals (82, 79.6 %) (Table 1). Half of 
the hospitals (52, 50.5 %) had the Saudi Central 
Board of Accreditation for Healthcare Institutions 
(CBAHI). However, only 30 (29.1%) had Joint 
Commission International (JCI) accreditation.  
 
Table 1: Demographic characteristics of the 
participating pharmacists 
 
Variable N (%) 
Pharmacist’s affiliation  
Ministry of Health 82 (79.6) 
Ministry of Defense 7 (6.8) 
National Guard 10 (9.7) 
Other 4 (3.9) 
Gender  
Male 78 (75.7) 
Female 25 (24.3) 
Nationality  
Saudi 83 (80.6) 
Non-Saudi 20 (19.4) 
Age  
20–30 51 (49.5) 
31–40 35 (34) 
41–50 15 (14.6) 
>50 2 (1.9) 
Degree type  
BPharm 72 (69.9) 
PharmD 19 (18.4) 
MSc 7 (6.8) 
PhD 5 (4.9) 
Position of pharmacist  
Staff 53 (51.5) 
Supervisor 31 (30.1) 
Assistant director 4 (3.9) 
Director 12 (11.7) 
Other 3 (2.9) 
 
The majority of the pharmacists were Saudi 
nationals and 51 (49.5 %) were in the age group 
of 20–30 years old. As well, 72 (69.9 %) 
pharmacists had a BPharm degree. Regarding 
the positions of the pharmacists, the majority 
were staff pharmacists (53, 51.5 %) and 
supervisors (31, 30.1 %). The participants had an 
average of 7.8 years of experience (Table 1). 
 
Regarding pharmacists’ knowledge about 
pharmacovigilance, only 56 (54.4 %) could 
correctly identify the WHO definition of ADRs, 
while 53 (51.5 %) of the pharmacists could 
correctly define the term pharmacovigilance in 
their own words and 66 (64.1 %) could 
differentiate between medication errors and 
ADRs (Table 2). 
 
Regarding pharmacists’ experience with ADR 
reporting, 46 (44.7 %) said that they have made 
a suspected ADR report, 34 (33 %) of whom 
made the report in their current location of 
practice. Slightly less than half of the 
pharmacists (50, 48.5 %) said that they are 
familiar with the SFDA system of suspected ADR 
reporting. However, when asked how they 
learned about the SFDA, 13 (12.6 %) learned 
from SFDA officials, 5 (4.9 %) learned from a 
colleague, 17 (16.55 %) learned from MOH 
official memos, one (1 %) learned from the 
media, and 14 (13.6 %) learned from the SFDA 
website (Figure 1). As well, 67 (65 %) said that 
they are familiar with the policy and procedures 
for reporting ADRs in their hospitals, 61 (59.2 %) 
of whom said they have easy access to the 
policy and procedures and can easily find the 
form to report suspected ADRs. However, of 
these, only 55 (53.4 %) were aware of the 
location where they should send the report if they 
were to encounter a suspected ADR (Table 3). 
 
The majority of the pharmacists (N = 95, 92.2 %) 
believed that patient safety is the most important 
goal of suspected ADR reporting (Figure 2). 
Suspected ADR reporting was considered a 
professional obligation by 54 (52.4 %), a means 
for pharmacists to get closer insight into drug-
related problems by 69 (67 %), a duty of the 
prescribing physician by 28 (27.2 %), and a duty 
of the manufacturer by 16 (15.5 %).  
 
 








Definition of ADRs according to the World Health Organization 56 (54.4) 47 (45.6) 
Definition of pharmacovigilance 53 (51.5) 50 (48.5) 
Knowledge of the difference between ADRs and medication errors 66 (64.7) 37 (36.3) 
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Over the course of your practice, have you made a suspected ADR report? 
 
46 (44.7) 57 (55.3%) 
If the answer to the previous question is “yes,” did you make that report in your 
current location of practice? 
 
34 (33) 69 (67) 
Are you familiar with the SFDA system of suspected ADR reporting? 
 
50 (48.5) 53 (51.5) 
Are you familiar with the policy and procedures for reporting ADRs in your 
hospital? 
 
67 (65) 36 (35) 
If the answer to previous question is “yes,” do you have easy access to the 
policy and procedures, and can you easily find the form to report suspected 
ADRs? 
 
61 (59.2) 42 (40.8) 
If the answer to previous question is “yes,” are you aware of where you should 
send the report if you were to encounter suspected ADRs? 
55 (53.4) 48 (46.4) 
 
 
Figure 1: How participants learn’t about ADR report 
 
Pharmacists’ motivations to report ADRs were 
associated with a new medication (18, 17.5 %), 
with a new ADR to an old medication (N = 23, 
22.3 %), with the seriousness of the ADR (N = 
41, 39.8 %), with the severity of the ADR (N = 
34, 33 %), and with the frequency of the ADR (N 
= 24, 23.3 %) (Table 4). 
 
 






Suspected ADR reporting is considered   
A professional obligation of pharmacists 54 (52.4) 49 (47.6) 
A means for pharmacists to get a closer insight into drug-related 
problems 
69 (67) 34 (33) 
A duty of the prescribing physician 28 (27.2) 75 (72.8) 
A duty of the manufacturer 
 
16 (15.5) 87 (84.5) 
What is your motivation to report an ADR?   
Association with a new medication 18 (17.5) 85 (82.5) 
A new ADR to an old medication 23 (22.3) 80 (77.7) 
The seriousness of the ADR 41 (39.8) 62 (60.2) 
The severity of the ADR. 34 (33) 69 (67) 
The frequency of the ADR. 24 (23.3) 79 (76.7) 
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Figure 2: What is the most important goal of suspected ADR reporting? 
 
Barriers to ADR reporting were a lack of access 
to ADR reporting forms and/or complicated forms 
(N = 22, 21.4 %), a lack of adequate time to 
provide ADR reporting (N = 33, 32 %), a lack of 
pharmacovigilance training (N = 48, 46.6 %), a 
lack of motivation to report ADRs (N = 25, 24 %), 
a sacrificing of reporter image (N = 7, 6.8 %), a 
fear of liability (N = 13, 12.6 %), and other (N =  
10, 9.7 %) (Table 5). 
 
Several factors that encourage ADR reporting 
were identified by the participants, including 
training about pharmacovigilance, increasing 
community awareness of ADR reporting, and 
feedback regarding the most recent ADRs 
reported to the SFDA (Table 6). 
 






Lack of access to ADR reporting forms/complicated forms 22 (21.4) 81 (78.6) 
Lack of adequate time to provide ADR reporting 33 (32) 70 (68) 
Lack of pharmacovigilance training 48 (46.6) 55 (53.4) 
Lack of motivation to report 25 (24.3) 78 (75.7) 
Could sacrifice prescriber/pharmacist image 7 (6.8) 96 (93.2) 
Fear of liability 13 (12.6) 90 (87.4) 
Other 10 (9.7) 93 (90.3) 
 
Table 6: Factors that encourage ADR reporting 
 
Training of healthcare professionals on the importance of pharmacovigilance and identification and reporting of 
ADRs. 
Organizing campaigns to raise the awareness of the community regarding ADR reporting and give easy access 
to all community levels, either electronically or manually. 
Distribution of regular circular concerning the recent recognized and approved ADRs and the most identified 
organizations regarding contributions to reporting. 
Identifying special healthcare staff to follow ADR identification and reporting. 
Motivation of healthcare professionals to report ADRs through CME hours, financial incentives, or holidays. 
Providing a safe environment for the person who reported the ADR so no one can make him or her liable or 
regretful. 
Ease the communication between healthcare professionals and the SFDA through social media, such as 
Facebook, Twitter, and WhatsApp, which are widely used in Saudi Arabia. 
Establish patient safety units in the hospitals with the responsibility of ADR reporting and increasing the 
awareness of healthcare staff about patient safety. 
Increase patients’ awareness about ADRs and ask them if they experience any ADRs during the patient 
counseling process. 
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This study is the first to assess the knowledge, 
attitudes, and experiences of hospital 
pharmacists working in government hospitals 
and primary care centers regarding 
pharmacovigilance in the Al Madinah Al 
Munawarah region. A self-reported questionnaire 
was used to ensure that the information obtained 
in this study is from the pharmacists and that 
they were not influenced by the researcher. The 
finding of this study mainly represents the 
opinions of Saudi pharmacists and they should 
be targeted for any intervention in the future.  
 
Although few recent studies were conducted in 
the hospital settings [19,20], the majority of the 
studies were conducted in community pharmacy 
settings where most of the pharmacists are 
expatriates, and the findings of those studies 
perhaps do not represent Saudi Arabia [9-11].In 
addition, the studies that were conducted in the 
hospital settings have targeted all healthcare 
professionals, and the current study has 
concentrated on hospital and primary care 
pharmacists only. Therefore, it is argued that this 
study presents the knowledge, attitudes, and 
experiences of the local Saudi pharmacists, and 
it could help policy makers to understand the 
current situation of pharmacovigilance practices 
among Saudi pharmacists.  
 
Regarding the pharmacists’ knowledge about the 
WHO definition of ADRs, 54.4 % had correctly 
defined the term. In contrast, a previous study 
reported that 92 % of the community pharmacists 
in the Eastern region of Saudi Arabia knew the 
correct definition of ADRs [11]. In addition, about 
half knew the definition of pharmacovigilance. A 
recent study from Riyadh reported that 55 % of 
healthcare professionals did not know the correct 
definition of pharmacovigilance. In addition, 64 % 
could not differentiate between a medication 
error and an ADR. It is obvious there is a lack of 
knowledge about pharmacovigilance aspects, 
and urgent interventions are required. 
Pharmacists are expected to educate patients 
about patient safety; therefore, to help them do 
their job efficiently, the hospital authorities in 
collaboration with the SFDA should undertake 
training programs to improve hospital 
pharmacists’ knowledge and help them 
strengthen their role.  
 
The majority of the pharmacists surveyed (55.3 
%) have never reported ADRs over the course of 
their practice, and the majority were also 
unfamiliar with the SFDA ADR reporting system. 
This finding is similar to studies from central 
Saudi Arabia and the Eastern regions, as the 
majority of the pharmacists were unaware of the 
ADR reporting system [9-11]. The main reason 
for this might be the lack of orientation and 
awareness initiatives from the SFDA, the media, 
and the MOH. Similar to a previous Saudi study, 
an overwhelming majority of the pharmacists 
believed that patient safety is the most important 
goal of ADR reporting. 
 
Limitations of the study  
 
The study findings cannot be generalized to all 
pharmacists in Saudi Arabia. A similar study is 




Based on this study’s findings, the rules and 
regulations of SFDA should be improved in Al 
Madinah Al Munawarah region. SFDA should 
strengthen the role of their representatives who 
should follow up on pharmacovigilance activities, 
including the dissemination of updates on the 
safety of medications, the promotion of 
spontaneous ADR reporting initiatives among 
pharmacists, as well as organize educational 
events, including workshops and conferences for 
pharmacists and other healthcare professionals 
to explain the role and activities of Saudi 
Pharmacovigilance Center. The objective of 
these activities should be to increase the 
awareness of pharmacists about 
pharmacovigilance and minimize barriers to ADR 
reporting. Simple training on the methods of ADR 
reporting, especially online reporting system of 
ADRs, might make a big difference in the 
awareness, reporting rate, and knowledge of 
pharmacists about spontaneous ADR reporting, 
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